Skip to main content
. 2009 Oct 28;84(1):261–269. doi: 10.1128/JVI.01528-09

TABLE 3.

Comparison of IC50s for CD4 reagents and commonly studied broadly neutralizing anti-HIV-1 Abs

Clade and Env IC50 (nM)a
CD4HC-(GS7)-IgGE51 CD4HC-(GS9)-IgGE51 CD4HC,LC-(GS7)-IgGE51 CD4HC-(GS7)-IgG17b CD4HC-(GS7)-IgGm9 CD4HC-(GS7)-IgG412d CD4HC-(GS7)- IgGanti-gD CD4-IgG2 CD4-Fc CD4 4E10 b12 2G12 2F5 PG9 PG16
Clade B
    SF162.LS 0.37 <0.26 ND <0.26 ND ND ND ND ND 2.3 0.07 0.06 4.0 0.68 >330 >330
    PVO.4 12 7.1 9.8 7.0 27 14 5.2 27 300 310 45 >330 8.0 >330 27 36
    CAAN5342.A2 14 6.8 ND 7.5 110 90 25 41 870 750 19 >330 >330 24 38 59
    WITO4160.33 3.2 1.6 5.5 1.4 17 8.2 4.6 8.0 120 250 2.1 20 7.3 4.1
    AC10.2.29 7.3 2.8 >420 3.5 51 ND 14 11 230 400 2.1 12 >330 8.8
    SC422661.8 7.0 5.7 10 7.4 28 14 6.7 14 240 220 6.2 1.3 14 4.8 5.3 7.5
    6535.30 1.7 1.1 9.8 0.8 6.8 ND 1.5 13 29 37 1.4 9.1 13 13 1.5 250
    THRO4156.18 2.8 1.8 ND ND 4.7 5.1 2.6 2.3 12 14 2.1 3.2 >330 >330 83 8.9
    REJO4541.67 2.3 1.4 30 ND 8.4 ND 3.1 2.9 17 23 4.9 4.5 >330 4.1
    TRJO4551.58 20 11 ND ND 66 ND 35 19 500 940 31 >330 >330 >330 2.9 7.7
    QH0692.42 3.1 1.8 16 ND 10 9.7 1.0 2.3 14 23 9.7 1.9 19 6.8 >330 >330
    TRO.11 86 52 4.7 ND 31 ND 9.3 45 770 540 2.1 >330 2.7 >330 36 1.5
    RHPA4259.7 3.2 1.5 370 ND 34 20 5.2 5.2 82 84 48 0.6 >330 82
Clade C
    MW965.26 <0.26 <0.26 ND <0.26 ND ND ND ND ND
    ZM197M.PB7 22 12 >420 7.2 61 63 35 91 >1,000 180 3.5 130 >330 84
    ZM249.PL1 13 4.6 ND 4.1 83 42 19 30 1000 450 15 21 >330 >330
    ZM53M.PB12 2.8 1.1 ND 1.5 28 31 4.6 12 350 390 49 170 >330 >330
    ZM214M.PL15 7.0 6.0 >420 5.2 22 16 13 16 470 370 28 19 >330 >330
    Du156.12 51 35 >420 35 120 53 87 40 >1,000 630 1.4 5.2 >330 >330
    Du422.1 1.6 0.8 >420 1.3 150 85 68 40 630 420 4.9 1.3 >330 >330
    Du172.17 5.2 2.9 160 ND 21 28 8.8 8.6 56 79 2.1 6.5 >330 >330
    CAP45.2.00.G3 3.6 2.0 ND ND 46 11 20 6.3 >1,000 1200 18 4.5 >330 >330
    CAP210.2.00.E8 6.3 2.9 ND ND 18 20 7.7 3.4 50 160 8.3 130 >330 >330
    ZM233M.PB6 6.6 2.3 ND ND 42 40 11 33 460 140 8.3 >330 >330 >330
    ZM109F.PB4 0.52 <0.26 ND ND 2.1 2.0 0.52 0.29 3.1 9 4.2 >330 >330 >330
    ZM135M.PL10a 13 9.3 ND ND 71 43 22 8.0 420 280 4.2 >330 >330 >330
Clade A
    DJ263.8 <0.26 <0.26 ND <0.26 ND ND ND ND ND
    Q23.17 3.6 2.1 >420 1.8 69 53 15 18 530 120 >330 >330 50
    Q842.d12 45 43 >420 33 200 86 110 90 >1,000 97 >330 >330 59
    Q259.d2.17 2.7 1.8 >420 1.8 43 38 12 13 93 99 >330 >330 72
    3718.v3.c11 19 9.4 >420 19 ND 94 55 41 >1,000 80 >330 >330 23
    0330.v4.c3 2.4 1.3 9.3 1.0 ND 12 ND 13 130 40 >330 4.7 65
    3415.00 16 8.1 12 10 ND 18 ND 90 640 160 160 14 250
Geometric mean 5.0 2.9 75 2.9 32 25 11 14 210 150 10 33 110 78 27 33
Arithmetic mean 12 7.2 220 7.1 51 36 22 25 440 320 30 150 240 190 96 110
a

IC50s for the 4E10, b12, 2F5 Abs and CD4 were taken from previously reported results (21, 22) or were provided by the CAVD neutralization core. IC50s for 2G12 were taken from references 21 and 22 and converted to molar concentrations, assuming the monomeric form. PG9 and PG16 were tested on a larger panel of viruses (35), but only those that overlapped with our panel are reported in this table. Over a 162-pseudovirus panel, PG9 and PG16 had geometric mean IC50s of 5.7 and 5.5 nM, respectively. In calculating average IC50s, measurements outside of the range of the assay (indicated by > or < symbol) were assigned to that limiting value. ND, not determined.